Masimo (NASDAQ:MASI) Earns Buy Rating from Stifel Nicolaus

Masimo (NASDAQ:MASI)‘s stock had its “buy” rating reiterated by equities researchers at Stifel Nicolaus in a research report issued on Friday,Benzinga reports. They presently have a $190.00 price target on the medical equipment provider’s stock, up from their prior price target of $170.00. Stifel Nicolaus’ target price would suggest a potential upside of 9.85% from the company’s previous close.

A number of other analysts also recently weighed in on the company. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target on the stock in a research note on Wednesday, November 6th. Wells Fargo & Company increased their price target on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. BTIG Research upped their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Piper Sandler lifted their price target on shares of Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $167.00.

Masimo Price Performance

Shares of NASDAQ MASI opened at $172.96 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market cap of $9.26 billion, a PE ratio of 119.28 and a beta of 0.97. The stock has a fifty day moving average price of $143.48 and a 200 day moving average price of $128.00. Masimo has a 1-year low of $91.60 and a 1-year high of $174.34.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. The business had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.63 earnings per share. Sell-side analysts forecast that Masimo will post 4.04 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. FMR LLC grew its holdings in Masimo by 41.2% during the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after buying an additional 1,970,883 shares during the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Masimo by 42.1% in the second quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock valued at $153,314,000 after acquiring an additional 360,497 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Masimo by 107.8% during the second quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock valued at $85,347,000 after acquiring an additional 351,523 shares during the last quarter. Bamco Inc. NY purchased a new stake in Masimo during the 1st quarter worth about $50,781,000. Finally, Westfield Capital Management Co. LP raised its stake in Masimo by 23.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock valued at $185,869,000 after purchasing an additional 262,370 shares during the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.